ArmonAir RespiClick FDA Approval History
FDA Approved: Yes (First approved January 27, 2017)
Brand name: ArmonAir RespiClick
Generic name: fluticasone propionate
Dosage form: Inhalation Powder
Company: Teva Pharmaceuticals USA, Inc.
Treatment for: Asthma, Maintenance
ArmonAir RespiClick (fluticasone propionate) is an inhaled corticosteroid in a breath-activated, multi-dose dry powder inhaler formulation for the treatment of asthma.
Development Timeline for ArmonAir RespiClick
|Jan 31, 2017||Approval Teva Announces FDA Approval of ArmonAir RespiClick (fluticasone propionate) for Maintenance Treatment of Asthma|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.